Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.56 |
| ▸ | S100A4 | P26447 | 2/20 | 0.53 |
| ▸ | PTPRC | P08575 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL35211484 | 1.00 | MAPT (0.56) | MAPTRECQLKMT2AMCL1RXFP1 | |
| SCHEMBL2333693 | 0.90 | MAPT (0.50) | MAPTRECQLKMT2AMCL1RXFP1 | |
| SCHEMBL4573599 | 0.89 | MAPT (0.53) | MAPTRECQLKMT2AMCL1RXFP1 | |
| SCHEMBL768880 | 0.89 | MAPT (0.53) | MAPTRECQLKMT2AMCL1RXFP1 | |
| SCHEMBL8499259 | 0.85 | MAPT (0.66) | MAPTRECQLKMT2AMCL1RXFP1 | |
| SCHEMBL16625981 | 0.83 | MAPT (0.51) | MAPTRECQLKMT2AMCL1RXFP1 | |
| SCHEMBL8597074 | 0.83 | MAPT (0.74) | MAPTRECQLKMT2AMCL1RXFP1 | |
| SCHEMBL16131516 | 0.83 | MAPT (0.51) | MAPTRECQLKMT2AMCL1RXFP1 | |
| SCHEMBL16098756 | 0.82 | LMNA (0.47) | MAPTRECQLKMT2AMCL1RXFP1 | |
| SCHEMBL31456583 | 0.80 | MAPT (0.51) | MAPTRECQLKMT2AMCL1RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11571407-B2 | Bicalutamide analogs or (S)-bicalutamide as exocytosis activating compounds for use in the treatment of a lysosomal storage disorder or glycogenosis | BCN PEPTIDES, S.A. (ES) | 2023-02-07 | — | — | US | claimed |
| CN-105828811-B | Bicalutamide analogs or (S) -bicalutamide as exocytosis activating compounds for use in the treatment of lysosomal storage disorders or glycogen storage diseases | BCN肽类股份有限公司 | 2022-04-08 | — | — | CN | claimed |
| US-20090163547-A1 | INDENE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-06-25 | — | — | US | claimed |
| CN-101356149-A | Indene derivatives, their preparation and use as medicaments | ESTEVE LABOR DR (ES) | 2009-01-28 | — | — | CN | claimed |
| EP-1960343-A2 | INDENE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | Laboratorios del Dr. Esteve S.A. (ES) | 2008-08-27 | — | — | EP | claimed |
| WO-2007054257-A2 | INDENE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-05-18 | — | — | WO | claimed |
| US-20260125359-A1 | HETEROARYL COMPOUNDS AS MULTI-TARGET PROTEIN KINASE INHIBITORS | FUJIAN HAIXI PHARMACEUTICALS CO LTD (CN) | 2026-05-07 | — | — | US | disclosed |
| EP-3597184-B1 | INDANONE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS OR OPTICAL ISOMERS THEREOF, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING VIRAL DISEASES | KOREA RES INST CHEMICAL TECH (KR) | 2026-03-04 | — | — | EP | disclosed |
| CN-113164495-B | Covalent targeting of E3 ligases | 加利福尼亚大学董事会 | 2025-04-22 | — | — | CN | disclosed |
| US-20250120982-A1 | COVALENT TARGETING OF E3 LIGASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-04-17 | — | — | US | disclosed |
| US-12161648-B2 | Covalent targeting of E3 ligases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-12-10 | — | — | US | disclosed |
| EP-4360710-A2 | 1,3-DI-OXO-INDENE DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT OR OPTICAL ISOMER THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS AN ANTIVIRAL, ACTIVE INGREDIENT | Korea Research Institute of Chemical Technology (KR) | 2024-05-01 | — | — | EP | disclosed |
| CN-115584073-B | Environment-friendly blown film and production process thereof | 郑州市彦峰塑料包装有限公司 | 2024-02-20 | — | — | CN | disclosed |
| US-RE37438-E1 | Acetamidine derivatives and their use as inhibitors for the nitric oxide synthase | GLAXO WELLCOME INC. | 2001-11-06 | — | — | US | disclosed |
| WO-1999052857-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM PLC (GB) | 1999-10-21 | — | — | WO | disclosed |
| US-5866612-A | Acetamidine derivatives and their use as inhibitors for the nitric oxide synthase | GLAXO WELLCOME INC. (US) | 1999-02-02 | — | — | US | disclosed |
| US-4442296-A | LARVICIDES | FMC CORPORATION (US) | 1984-04-10 | — | — | US | disclosed |
| US-4408057-A | 4-Heterocyclic-substituted-2-indanyl alcohols and insecticidal ester derivatives | FMC CORPORATION (US) | 1983-10-04 | — | — | US | disclosed |
| US-4368205-A | 4-Heterocyclic-substituted-2-indanyl alcohols and insecticidal ester derivatives | FMC CORPORATION (US) | 1983-01-11 | — | — | US | disclosed |
| US-3988460-A | Cyclopentenoquinolone compounds for treating bacterial infections | BOEHRINGER MANNHEIM G.M.B.H. (DT) | 1976-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11571407-B2 | Bicalutamide analogs or (S)-bicalutamide as exocytosis activating compounds for use in the treatment of a lysosomal storage disorder or glycogenosis | GBA1, GAA, GBA3 | MAPT 831/4885RECQL 3252/4885KMT2A 2320/4885 |
| US-12161648-B2 | Covalent targeting of E3 ligases | RNF114, RNF4, RNF168 | MAPT 961/4885RECQL 1305/4885KMT2A 501/4885 |
| US-20260125359-A1 | HETEROARYL COMPOUNDS AS MULTI-TARGET PROTEIN KINASE INHIBITORS | ERBB2, ERBB3, ARRB1 | MAPT 4548/4885RECQL 4068/4885KMT2A 2787/4885 |
| US-20250120982-A1 | COVALENT TARGETING OF E3 LIGASES | STUB1, XIAP, RBX1 | MAPT 2132/4885RECQL 1185/4885KMT2A 869/4885 |
| US-20090163547-A1 | INDENE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | HTR6, HTR5A, HTR1A | MAPT 1872/4885RECQL 2263/4885KMT2A 4585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.